SIK1 and neoplasm: In contrast to other cancer types where SIK1 acts as a tumor suppressor, Hartono et al. found that SIK1 depletion with siRNA or shRNA reduced the viability of two DSRCT cell lines, indicating an oncogenic role for SIK1 in DSRCT (Hartono et al., 2022).